Previous Article | Next Article ![]()
Journal of Virology, December 2003, p. 12562-12571, Vol. 77, No. 23
0022-538X/03/$08.00+0 DOI: 10.1128/JVI.77.23.12562-12571.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Division of Infectious Diseases and Division of Pediatric Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Received 1 April 2003/ Accepted 18 August 2003
|
|
|---|
|
|
|---|
NORs have been recently found to recognize human histo-blood group antigens (HBGAs) as receptors (14, 16-18, 26, 30). The recognition of HBGAs by NORs was demonstrated to be strain specific. So far, four distinct binding patterns of NORs, which were defined by the ABO, Lewis, and secretor types of human hosts (16), have been described. Human HBGAs are complex carbohydrates linked to glycoproteins or glycolipids that are present on the red blood cells and mucosal epithelial cells or as free antigens in biological fluids, such as blood, saliva, intestinal contents, and milk (29). These antigens are synthesized by sequential additions of monosaccharides to the antigen precursors by several glycosyltransferases that are genetically controlled and known as the ABO, Lewis, and secretor gene families (29).
The prototype Norwalk virus (NV) represents one of the four binding patterns, and it binds to HBGAs of type A and O secretors but not of nonsecretors (16, 26). Human volunteer studies showed that saliva from volunteers with nonsecretor status did not bind to NV and that nonsecretors were naturally resistant to NV infection following the challenge (26). In our studies, NV did not bind to saliva of type B secretors (16). A retrospective study of volunteers challenged with NV showed that type B individuals had a lower rate of infection by NV than individuals of other blood types following the challenge (17). The other three binding patterns recognize A, B, and O secretors (strain VA387), A and B secretors (MOH), and Lewis-positive secretors and nonsecretors (strain VA207) (16). By analogy, we predict that each of the three binding patterns may have its own host ranges defined by human blood types, although direct evidence linking HBGAs with infection of these strains remains lacking.
In this study, we addressed the question of structural determinants of NOR capsid binding to HBGA receptors. Using computational approaches, we identified a putative receptor binding site on the surface of the P2 domain. Mutagenesis data revealed that this putative binding pocket is indeed involved in binding to HBGAs. More importantly, single amino acid changes within this pocket knocked out the binding completely, whereas shifting mutations resulted in changes of binding patterns, highlighting the importance of this newly identified site for virus-host interaction.
|
|
|---|
Construction of mutant NOR capsids by site-directed mutagenesis. A series of mutant NOR capsids of strains VA387 (23) and MOH (11) were constructed by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). The capsid genes of VA387 and MOH were cloned into pGEM-T vector (Promega, Madison, Wis.). Primers for site-directed mutagenesis were designed according to manufacturer's instruction with at least 15 nucleotides at both ends to the nearest mutated nucleotides. For strain VA387 the following primers were used: GTTGTCCAACCACAAAGTGCCAGTTGCACGACTGATGGC (NGR/SAA), CCAAGGTGTTTTACGGTCCACGTGCAGAC (NGR/NAR), GTCAATATCTGCACCTTCAGTGCGGCTGTCACCCACATTGCAG (RGD/SAS), CTGCACCTTCGCAGGGGATGTCACCCAC (RGD/AGD), CTGCACCTTCAGAGCGGATGTCACCCAC (RGD/RAG), CTGCACCTTCAGAGGGAAAGTCACCCACATTGCAG (RGD/RGK), GTCATGACTATATAATGGCTTTGGCATCTCAAAATTGG (N/A), GCTCACCCAAACCGCAAGAGAGGATGGC (T/A), and GACACAAACAATGATTTTGCAACTGGCCAAAACACG (Q/A). For strain MOH, the following primers were used: GTTGTTCAGCCACAGAGTGCTAGCGTCACATTAGATGGG (NGR/SAS), TGTAACATTTGCACCTTCGAGGGGGACGTGACAGGGCAG (SIRGK/TFRGD), CACATGTGGAACATGAACCTCACAAACCTAAATGGG (LEI/MNL), GGTGTGCTCAGCCAGACAACCAGAGGCGAAAGCAAC (RN/TT), and AACACCAATGATTTTCAAACCCAACCAACAAAATTC (VEN/FQT). Three chimera capsids of MOH with an 11-amino acid (aa) replacement from VA387 at site II (chimera 1) and/or site IV (chimera 2) were made by overlapping PCRs. These were achieved by designing a pair of primers that can anneal to the positions adjacent to the regions of replacement and have the overlapping sequences (mutated sequences) at their 5' ends (ATTTTGAGATGCCAAATTCATTATATAGTCATGATTAGGGACCTGCCCTGTCAC and CATGACTATATAATGAATTTGGCATCTCAAAATAACCTAAATGGGACGCAATTTG for chimera 1; CGTGTTTTGGCCAGTTTGAAAATCATTGTTTGTCCAAGTTCCAATTTGCACTAAG and ACAAACAATGATTTTCAAACTGGCCAAAACACGTTCACCCCAATTGGTTTGAAT for chimera 2). PCR products from these two primers, together with a primer at the beginning or end of the coding region, were gel purified and used together as templates for a second PCR using primers at both ends of the coding region of the capsid gene. Chimera 3, which contains mutations of chimera 1 and 2, was prepared by the same method, with chimera 1 as the starting construct. Mutated sequences were validated by sequencing.
Expression and purification of mutated capsid proteins. Mutated capsids were expressed in Spodoptera frugiperda (Sf9) cells using the Bac-to-Bac baculovirus expression system (Invitrogen, Carlsbad, Calif.) according to the manufacturer's manual. Briefly, the mutated capsid genes were subcloned into pFastBac1 donor plasmid and transposed into bacmid. Sf9 cells were then infected with wild-type baculovirus or the baculovirus recombinant bacmids containing the mutated capsid genes. Infected cells were harvested between the third and the sixth generation. After a few freeze-thaw cycles, the cell lysates were centrifuged at 5,000 x g for 15 min to separate the cell debris. The clear supernatants were centrifuged again at 10,000 x g for 30 min to spin down large protein complexes or baculovirus particles. VLPs in the supernatant were then purified by centrifugation at 100,000 x g for 150 min. For further purification of the VLPs, the resuspended pellets were separated using sucrose step gradient (5 to 45%) centrifugation, as described previously (20, 21). The recombinant proteins were stored in 1x phosphate-buffered saline, pH 7.4, at -70°C. To quantify the expressed proteins, a small aliquot of purified samples was separated on a sodium dodecyl sulfate-10% polyacrylamide gel. A series of dilutions of the quantitated recombinant wild-type VLPs of the two strains (VA387 and MOH) were loaded on the same gel as standards. Proteins were then transferred to a nitrocellulose membrane for Western blot analysis with hyperimmune antibodies raised in guinea pigs against the wild-type capsids of VA387 or MOH, respectively. The protein concentrations in the samples were determined by comparing the signal intensities using the image analysis software Scion Image (4.0.2; Scion Corporation) after immunodetection. Because we found background bands from wild-type baculovirus in some Western blot experiments (see Fig. 4), we did not use enzyme immune assays to determine the concentrations of mutated capsids.
![]() View larger version (82K): [in a new window] |
FIG. 4. Western blot analysis of mutant capsid proteins expressed in Sf9 culture. (A) Mutants from VA387; (B) mutants from MOH. Each sample contained partially purified VLPs corresponding to an equal amount of original insect culture. The proteins were detected by hyperimmune guinea pig antibodies against recombinant wild-type VA387 (rVA387) (A) and MOH (rMOH) (B) capsids. In most cases, two major bands at 58 and 50 kDa were observed for each recombinant capsid. Arrows show the background bands from baculovirus. (C) VLPs from mutated capsids. A, VA387 wild type; B, VA387 RGD/AGD mutant; C, VA387 RGD/RAD mutant; D, VA387 N/A mutant; E, VA387 T/A mutant; F, VA387 Q/A mutant; G, MOH LEI/MNL mutant; H, MOH TN/TT mutant; I, MOH VEN/FQT mutant, J, MOH wild type. Magnification, x31,500.
|
Characterization of NOR capsid binding to HBGAs by saliva binding enzyme immune assays. Saliva binding enzyme immune assays were used to monitor recombinant VLP binding to HBGAs, as described previously (16). Briefly, saliva samples of known ABO, secretor and Lewis types were boiled at 100°C and centrifugation at 10,000 g for 5 min. The supernatant was then used to coat microtiter plates (Dynex Immulon; Dynatech, Franklin, Mass.) at a dilution of 1:1,000 in 1x phosphate-buffered saline (pH 7.4). After blocking with 5% dried milk (Blotto), known amounts of the wild-type recombinant capsid proteins or their mutated forms were added with a serial dilution. The bound capsid proteins were detected with hyperimmune guinea pig anti-NOR antisera, and by adding horseradish peroxidase-conjugated goat anti-guinea pig immunoglobulin G (ICN, Aurora, Ohio). The horseradish peroxidase activity was detected with a TMB kit (Kirkegaard & Perry Laboratories, Gaithersburg, Md.), and the signal intensities (optical density [OD]) were read with an enzyme immunoassay spectrum reader (Tecan, Durham, N.C.). In order to determine the binding affinity of the mutated capsids in relation with their wild-type one, all capsids were assayed for their binding to HBGAs of A-, B-, and O-type saliva within a comparable range of protein concentrations.
|
|
|---|
![]() View larger version (81K): [in a new window] |
FIG. 1. Sequence comparison of the P2 domain of NOR capsids. The strains representing the four binding patterns to human HBGAs are VA387, NV, MOH, and VA207. Four sites (I to IV) that are potentially responsible for building up a putative binding pocket are in bold. The NGR motif upstream of the P2 domain is also in bold. Strains VA387 (387) and Grimsby virus (GrV) bind to A-, B-, and O-type saliva. The binding patterns of the Bristol (BV) and Lordsdale viruses (LV) are unknown but they share over 95% amino acid identity with VA387 and Grimsby virus. The prototype NV is the only strain known to bind to A and O saliva. MOH and Mexico virus (MxV) bind to type A and B saliva. The binding patterns of their homologous strains Hillingdon virus (HIL) and Toronto virus (TV) remain to be determined. VA207 (207) binding to the Lewis epitope of secretors and nonsecretors. According to our preliminary results, a new cluster representative strain within genogroup I, Boxer (BX), also binds to the Lewis epitope (unpublished data), but additional characterization of this strain is necessary. The stars indicate conserved residues for all strains. Numbers on the right indicate the sequence position of capsid proteins.
|
![]() View larger version (51K): [in a new window] |
FIG. 2. Computational prediction of a plausible binding pocket on the surface of the NV capsid protein. The predicted pocket is located on top of the P2 domain and is composed of a conserved RGD-like motif (R291) and three strain-specific hot spots, N300, F335, and N368, that are located in close spatial proximity (see the text for details). Ball-and-stick models of the side chains indicate the critical residues surrounding the putative binding pocket. The oval represents the P1 domain of the capsid protein. The S domain is not shown. The Rasmol visualization program was used to prepare the figure.
|
![]() View larger version (21K): [in a new window] |
FIG. 3. Schematic representation of mutation constructs of NOR capsids used in this study. (A) Graphic representation of the P domains with emphasis on P2 domain. Arrows indicate the positions of the four sites that are predicted to build up the binding pocket. The conserved NGR motif is also indicated. (B) Mutants with mutations in the NGR motif and the four sites of the VA387 and MOH capsid proteins.
|
![]() View larger version (23K): [in a new window] |
FIG. 5. Binding curves of mutants with mutations related to the RGD-like motif. The x axes indicate the concentration of the capsid proteins, and the y axes indicate the ODs obtained from the saliva binding assay. (A) Mutants with amino acid changes of the entire RGD-like motif; (B) mutants with single amino acid change in the RGD-like motif; (C) mutant with longer sequences shifting from MOH to VA387. Data were averaged from at least two independent experiments. , A antigen; , B antigen; , H antigen (type O saliva).
|
![]() View larger version (10K): [in a new window] |
FIG. 8. Binding curves of mutants from VA387 (A) and MOH (B) with mutations related to NGR motif. The axes are the same as in Fig. 5. Data were averaged from at least two independent experiments. , A antigen; , B antigen; , H antigen (type O saliva).
|
Site III is critical for NOR capsid binding to human HBGAs. Sites II, III, and IV are located at the opening of the predicted binding pocket, and they are not conserved among strains representing different receptor binding patterns. Thus, they may be responsible for the strain specificity to HBGAs. However, site-directed mutagenesis analysis did not support the idea that site III is responsible for binding specificity. One VA387 mutant with a single amino acid change from T337 to A (Fig. 3) completely lost its binding to the HBGAs of A, B, and O types (Fig. 6). A double amino acid switch mutant at this position from RN of MOH to TT of VA387 not only did not gain binding to the H antigen but also lost binding to A and B antigens (Fig. 7). Two more mutants with mutations at site III plus mutations at sites II and/or IV (Fig. 3) also led to the same results. Taken together, our data indicated that site III plays a critical role in NOR capsid binding to human HBGAs, since even a single amino acid change can result in complete loss of binding.
![]() View larger version (27K): [in a new window] |
FIG. 6. Binding curves of mutants with single amino acid modification at sites II, III, and IV. The axes are the same as in Fig. 5. Data were averaged from at least two independent experiments. , A antigen; , B antigen; , H antigen (type O saliva).
|
![]() View larger version (16K): [in a new window] |
FIG. 7. Binding curves of shift mutants with sequence modifications from MOH to VA387 at sites II, III, and IV (A) and comparison of binding to H antigen with that of the wild type (B). (A) The axes are the same as in Fig. 5. Data were averaged from at least two independent experiments. , A antigen; , B antigen; , H antigen (type O saliva). (B) 1, LEI/MNL mutant; 2, VEN/FQT mutant; 3, RN/TT mutant; 4, MOH wild-type capsid. The y axis shows the OD of the saliva-binding assay.
|
The NGR motif is required for receptor binding. Sequence comparison of NOR capsid proteins revealed a highly conserved NGR motif that was found in all known human and animal enteric NORs. Moreover, the asparagine residue is conserved in all caliciviruses. This motif is located at 20 aa upstream of the RGD-like motif and at the interface between the P1-1 and P2 domains. Therefore, this motif is likely to play an important role in structure and function of NORs. The NGR motif has been found to be involved in the interaction with integrin for rotavirus (9). To test if this motif is also related to NOR receptor binding, the same knockout mutants (NGR/SAA) were constructed for both VA387 and MOH. Both mutants resulted in low yields of the recombinant capsid proteins and VLPs in the insect cells, less than one-quarter of that of other recombinant capsid proteins made in this study (Fig. 4). Saliva binding assay of these mutants showed no detectable binding activity (Fig. 8; data not shown). To further dissect the motif for its role in receptor binding, another mutant (NGR/NAR) with a single amino acid modification was made for strain VA387. Again, a low yield of the protein and no detectable binding to HBGAs were observed. Based on the above observations, we speculated that the NGR motif is important for the maintenance of capsid structure. The loss of the binding to HBGAs in NGR-related mutants is probably due to a local or global conformation change(s) of the capsids, which directly or indirectly affects the conformation of the binding pocket.
|
|
|---|
The two strains characterized in this study have multiple determinants for individual HBGAs. Our recent studies indicated that MOH recognizes the A (glucose residue) and B (N-acetyl-glucosamine residue) antigens, while VA387 recognizes the H antigen (1,2-fucosyl residue) in addition to the A and B antigens (16; Jiang et al., Am. Soc. Virol. Annu. Meet.). One question is how variations in the binding pocket contribute to recognition of these substrates. As demonstrated by our results, site III is responsible for binding but not for strain specificity, and single or double amino acid changes at this site resulted in loss of binding to all epitopes (A, B, and/or H) for both strains. The other three sites corresponded to certain levels of strain-specific binding but did not account fully for the binding specificity. Therefore, we hypothesize that the binding specificities of NOR capsids may not be determined by a linear epitope or a single residue; instead, they may involve conformational epitopes and combination of several residues surrounding the pocket.
In our recent NOR receptor studies, we have observed that saliva samples from type A individuals could block VA387 and MOH binding to type B saliva and vice versa, suggesting that both A and B antigens share the same binding site. Once this site is occupied, it is no longer accessible to other molecules. Thus, we assume that each capsid protein has a single pocket. The overall shape and chemical characteristics (e.g., charge distribution) of the pocket is likely to be different for different strains due to different side chains of the residues surrounding the pocket, providing fitness to a specific group of HBGAs.
The identification of the RGD-like motif in the NOR capsids is an important finding, as it led to the prediction of the binding pocket in the P2 domain. The location of the motif at the bottom of the pocket suggested that it interacts directly with HBGAs. NORs are genetically diverse, but the RGD-like motif is conserved among all NORs and the lagoviruses. The first amino acid of the motif of NORs is a basic and positively charged arginine (R) or lysine (K) residue, except for the bovine Newbury strain, which contains a valine (V). In lagoviruses it is either arginine or serine. The second amino acid of the motif is highly conserved throughout the two genera, and the third amino acid is more variable. The recent discovery of NORs in animals raised the questions of zoonotic transmission or animal reservoirs for human NORs. However, direct evidence for interspecies transmission of NORs is still lacking. Recently, a large surveillance of bovine enteric caliciviruses in the United Kingdom between 1976 and 2000 showed that they represent a distinct genogroup III of NORs but did not pose a threat to human health (34). Human blood types are unique among most mammal species, and known NORs mainly infect humans. A recent study showed that the prototype NV does not recognize blood antigens of many nonhuman mammals except chimpanzees (18). Most interestingly, the rabbit calicivirus recognizes the human H type 2 antigen (39). Thus, the RGD-like motif could be a genetic marker for host specificity between animal and human caliciviruses. Two exceptions, however, have been found so far. One is the Jena strain of bovine NORs (27), which contains an off-location RGD motif relative to those in human and rabbit strains (data not shown). The other exception is the swine NOR, which belongs to genogroup II and reveals a RGT motif (44). Whether these exceptional animal strains are truly zoonotic or of human origin and whether they pose a threat to human health remains unclear.
In contrast to the RGD-like motif, the role of the NGR motif may be significantly different. This motif is conserved among all animal and human NORs. Therefore, a common pressure not related to the host receptors must have selected it. The complete knockout of binding by mutations in this region suggests that this motif is indispensable. The location of this motif, near but not in the binding pocket, suggests that this motif is not directly involved in interaction with HBGAs. Thus, the lack of binding to receptors by VLPs containing NGR mutations indicates that the NGR motif may involve local conformation changes that perturb the structure of the binding pocket. The NGR motif is also likely to be required for capsid assembly, since mutations in this motif lead to low yields of the capsid proteins. Alternatively, the low yields are due to a low expression of the proteins. Low expression of mutated capsid proteins not due to conformational stability has been reported for mutations in other regions of the NV capsid (1, 45).
This is the first study to dissect the structure of NOR capsid in relationship with receptor binding. The attachment and entry of a virus to host cells could be the first step of viral infection. A precise map of binding domains and an elucidation of the structure of the interface between the receptor and viral capsid would facilitate understanding the virus-host interaction. This may lead to a discovery or design of specific compounds as antiviral drugs to block the virus infection. A growing number of viral and bacterial pathogens have been linked with HBGAs that serve as receptors for infection (2-5, 8, 12, 15, 25, 28, 37, 41-43). Although different pathogens cause different illness, they may share common mechanisms of interaction with HBGA receptors. NOR capsids are formed by a single capsid protein, making this system simpler than those of many other viral and bacterial pathogens. Our recent studies have described four binding patterns of NORs. The target HBGAs within each pattern have been clearly defined (16) (unpublished data). Thus, NORs could provide a unique model of pathogen-host interaction for the human HBGA system. Elucidation of this model promises to lead to new strategies for therapeutic control of emerging pathogens.
In this study we characterized only four sites within the P2 domain of NOR capsid. Whether additional sites within or adjacent to the predicted pocket are also involved in binding remains unclear. In addition, this study characterized two strains with closely related binding patterns, and both strains belong to the same genogroup of NORs. So far, at least 20 genetic clusters within three genogroups of NORs have been identified (13). Strains within the same genogroup can target different HBGA receptors, and strains in different genogroups can also have the same targets. Therefore, characterization of additional strains representing more genotypes and binding patterns is necessary. Finally, according to the biosynthetic pathways of HBGAs, the target antigens for individual binding patterns have been predicted. Thus, experiments using synthetic oligosaccharides representing these antigenic epitopes should be performed. Due to the unavailability of some of the synthetic oligosaccharides, our study used saliva-binding assays only. Further studies using defined oligosaccharides to confirm our results are necessary.
The research described in this article was supported by the National Institute of Allergy and Infectious Diseases (RO1 AI37093-6).
We thank Irene Hofmann for technical assistance.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»